Cadoret-Manier Onaiza

SEC source: 0001799355-26-000006 · wk-form4_1781813140.xml · derivative · entry 2

Cadoret-Manier Onaiza · CIK 0001799355 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,715

Underlying: Common Stock · 39,715 shares

Expires 2036-06-16

F2 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program.

F3 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date.

SEC source: 0001799355-26-000006 · wk-form4_1781813140.xml · nonDerivative · entry 1

Cadoret-Manier Onaiza · CIK 0001799355 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 178,156

F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program.

SEC source: 0001799355-26-000002 · form4-03042026_090309.xml · derivative · entry 5

Cadoret-Manier Onaiza · CIK 0001799355 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,427 shares

Expires 2033-01-11

F1 · kind: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent.

F3 · price: At the Effective Time, this option to purchase shares of the Issuer's common stock was fully vested and had an exercise price per share that was greater than the Per Share Price and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled for no consideration.

F3 · derivative.exercise_date: At the Effective Time, this option to purchase shares of the Issuer's common stock was fully vested and had an exercise price per share that was greater than the Per Share Price and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled for no consideration.

SEC source: 0001799355-26-000002 · form4-03042026_090309.xml · derivative · entry 4

Cadoret-Manier Onaiza · CIK 0001799355 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,937 shares

Expires 2033-06-15

F1 · kind: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent.

F3 · price: At the Effective Time, this option to purchase shares of the Issuer's common stock was fully vested and had an exercise price per share that was greater than the Per Share Price and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled for no consideration.

F3 · derivative.exercise_date: At the Effective Time, this option to purchase shares of the Issuer's common stock was fully vested and had an exercise price per share that was greater than the Per Share Price and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled for no consideration.

SEC source: 0001799355-26-000002 · form4-03042026_090309.xml · derivative · entry 3

Cadoret-Manier Onaiza · CIK 0001799355 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,000 shares

Expires 2034-01-21

F1 · kind: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent.

F2 · price: At the effective time of the Merger (the "Effective Time"), this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal to $14.00 (without interest) per share (the "Per Share Price") and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes.

F2 · derivative.exercise_date: At the effective time of the Merger (the "Effective Time"), this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal to $14.00 (without interest) per share (the "Per Share Price") and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes.

SEC source: 0001799355-26-000002 · form4-03042026_090309.xml · derivative · entry 2

Cadoret-Manier Onaiza · CIK 0001799355 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires 2035-06-05

F1 · kind: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent.

F2 · price: At the effective time of the Merger (the "Effective Time"), this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal to $14.00 (without interest) per share (the "Per Share Price") and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes.

F2 · derivative.exercise_date: At the effective time of the Merger (the "Effective Time"), this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal to $14.00 (without interest) per share (the "Per Share Price") and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes.

SEC source: 0001799355-26-000002 · form4-03042026_090309.xml · derivative · entry 1

Cadoret-Manier Onaiza · CIK 0001799355 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 33,000 shares

Expires 2034-06-06

F1 · kind: Pursuant to the Agreement and Plan of Merger, dated January 7, 2026 (as it may be amended from time to time, the "Merger Agreement"), by and among Ventyx Biosciences, Inc. ("Issuer") , Eli Lilly and Company ("Parent"), and Parent's wholly owned subsidiary, RYLS Merger Corporation ( "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger and becoming a wholly owned subsidiary of the Parent.

F2 · price: At the effective time of the Merger (the "Effective Time"), this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal to $14.00 (without interest) per share (the "Per Share Price") and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes.

F2 · derivative.exercise_date: At the effective time of the Merger (the "Effective Time"), this option to purchase shares of the Issuer's common stock had an exercise price per share that was less than or equal to $14.00 (without interest) per share (the "Per Share Price") and, pursuant to the terms of the Merger Agreement, at the Effective Time, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the total number of shares of common stock subject to the option, multiplied by (ii) the excess, if any, of the Per Share Price over the exercise price per share of such option, without interest and less any applicable withholding taxes.

SEC source: 0001628280-25-032726 · wk-form4_1750725593.xml · derivative · entry 2

Cadoret-Manier Onaiza · CIK 0001799355 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,059

Underlying: Common Stock · 54,059 shares

Expires 2035-06-18

F2 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program.

F3 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date.

SEC source: 0001628280-25-032726 · wk-form4_1750725593.xml · nonDerivative · entry 1

Cadoret-Manier Onaiza · CIK 0001799355 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 151,701

F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof. The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program.

SEC source: 0000950170-25-082978 · ownership.xml · derivative · entry 1

Cadoret-Manier Onaiza · CIK 0001799355 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2035-06-05

F1 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or, (ii) the day prior to the date of the Annual Meeting of the Issuer's stockholders next following the date the option was granted, in each case, subject to the reporting person continuing to be Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable vesting date.

SEC source: 0001628280-24-028598 · wk-form4_1718664608.xml · derivative · entry 1

Cadoret-Manier Onaiza · CIK 0001799355 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,243

Underlying: Common Stock · 40,243 shares

Expires 2034-06-14

F1 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program.

F2 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date.

SEC source: 0001415889-24-015989 · form4-06072024_080601.xml · derivative · entry 1

Cadoret-Manier Onaiza · CIK 0001799355 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,000

Underlying: Common Stock · 33,000 shares

Expires 2034-06-06

F1 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or, (ii) the day prior to the date of the Annual Meeting of the Issuer's stockholders next following the date the option was granted, in each case, subject to the reporting person continuing to be Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable vesting date.

SEC source: 0000874015-24-000104 · edgardoc.xml · nonDerivative · entry 2

Cadoret-Manier Onaiza · CIK 0001799355 · EVP, Chf GL Pdt Str & Oper Ofc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,825

F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Performance restricted Stock Unit Agreement and Grant Notice.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.60 to $49.62 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

SEC source: 0000874015-24-000194 · primary_doc.xml · nonDerivative · entry 1

Cadoret-Manier Onaiza · CIK 0001799355 · EVP,Chf GL Pdt Str & Oper Ofc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,788

F1 · shares: The original Form 4 filed on February 2, 2024 reported 2,125 restricted stock units sold by the reporting person which has been revised by this amendment to reflect the actual amount of shares sold and beneficially owned by Ms. Cadoret-Manier.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.60 to $49.62 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

F1 · balance_after: The original Form 4 filed on February 2, 2024 reported 2,125 restricted stock units sold by the reporting person which has been revised by this amendment to reflect the actual amount of shares sold and beneficially owned by Ms. Cadoret-Manier.

SEC source: 0000874015-24-000104 · edgardoc.xml · nonDerivative · entry 1

Cadoret-Manier Onaiza · CIK 0001799355 · EVP, Chf GL Pdt Str & Oper Ofc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,950

F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs") for the second performance period of the grant to the reporting person reported on January 19, 2022. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 150% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 150% based on actual achievement of the goal.

SEC source: 0001209191-24-002088 · doc4.xml · derivative · entry 1

Cadoret-Manier Onaiza · CIK 0001799355 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2034-01-21

F1 · derivative.exercise_date: The shares subject to the option shall vest on the one-year anniversary of January 21, 2024, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan, the "Plan") through such date, provided that in the event of a Change in Control (as such term is defined in the Plan), one hundred percent (100%) of the then-unvested and outstanding shares subject to the Option will accelerate and fully vest, subject to the reporting person continuing to be an Outside Director (as the term is defined in the Company's Amended and Restated Outside Director Compensation Policy) through the date of the Change in Control.

SEC source: 0000874015-24-000081 · edgardoc.xml · nonDerivative · entry 2

Cadoret-Manier Onaiza · CIK 0001799355 · EVP, Chf GL Pdt Str & Oper Ofc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,810

F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.35 to $50.43, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4.

SEC source: 0000874015-24-000081 · edgardoc.xml · derivative · entry 3

Cadoret-Manier Onaiza · CIK 0001799355 · EVP, Chf GL Pdt Str & Oper Ofc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,997

Underlying: Common Stock · 15,062 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-24-000081 · edgardoc.xml · nonDerivative · entry 1

Cadoret-Manier Onaiza · CIK 0001799355 · EVP, Chf GL Pdt Str & Oper Ofc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,374

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

SEC source: 0000874015-24-000052 · edgardoc.xml · derivative · entry 2

Cadoret-Manier Onaiza · CIK 0001799355 · EVP, Chf GL Pdt Str & Oper Ofc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,059

Underlying: Common Stock · 32,400 shares

Expires not disclosed

F3 · security: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-24-000052 · edgardoc.xml · derivative · entry 1

Cadoret-Manier Onaiza · CIK 0001799355 · EVP, Chf GL Pdt Str & Oper Ofc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,635

Underlying: Common Stock · 27,000 shares

Expires not disclosed

F1 · security: Grant to reporting person of Performance Restricted Stock Units (PRSUs) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F2 · derivative.exercise_date: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.

F2 · derivative.expiration_date: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.

SEC source: 0000874015-24-000020 · edgardoc.xml · derivative · entry 1

Cadoret-Manier Onaiza · CIK 0001799355 · EVP, Chf GL Pdt Str & Oper Ofc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,200

Underlying: Common Stock · 43,200 shares

Expires 2034-01-01

F1 · derivative.exercise_date: Grant on 01/02/2024 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2024. 25% of the shares subject to the option will vest and become exercisable on 01/02/2025. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0001209191-23-038184 · doc4.xml · derivative · entry 1

Cadoret-Manier Onaiza · CIK 0001799355 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,937

Underlying: Common Stock · 15,937 shares

Expires 2033-06-15

F1 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the Vesting Commencement Date (as defined below) or, (ii) the day prior to the date of the Annual Meeting of the Issuer's stockholders next following the date the option was granted, in each case, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable vesting date. The "Vesting Commencement Date" shall mean June 7, 2023.

SEC source: 0001628280-23-022557 · wk-form4_1686954661.xml · derivative · entry 2

Cadoret-Manier Onaiza · CIK 0001799355 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,237

Underlying: Common Stock · 49,237 shares

Expires 2033-06-15

F2 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program.

F3 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date.

SEC source: 0001628280-23-022557 · wk-form4_1686954661.xml · nonDerivative · entry 1

Cadoret-Manier Onaiza · CIK 0001799355 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,150

F1 · shares: The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program.

SEC source: 0000874015-23-000131 · edgardoc.xml · nonDerivative · entry 2

Cadoret-Manier Onaiza · CIK 0001799355 · EVP, Chf GL Pdt Str & Oper Ofc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,312

F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.19 to $36.50953 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

SEC source: 0000874015-23-000131 · edgardoc.xml · derivative · entry 3

Cadoret-Manier Onaiza · CIK 0001799355 · EVP, Chf GL Pdt Str & Oper Ofc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,659

Underlying: Common Stock · 5,667 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-23-000131 · edgardoc.xml · nonDerivative · entry 1

Cadoret-Manier Onaiza · CIK 0001799355 · EVP, Chf GL Pdt Str & Oper Ofc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,894

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

SEC source: 0000874015-23-000090 · edgardoc.xml · nonDerivative · entry 2

Cadoret-Manier Onaiza · CIK 0001799355 · EVP, Chf GL Pdt Str & Oper Ofc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,227

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.60 to $40.70 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-23-000090 · edgardoc.xml · nonDerivative · entry 1

Cadoret-Manier Onaiza · CIK 0001799355 · EVP, Chf GL Pdt Str & Oper Ofc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,678

F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs") for the first performance period of the grant to the reporting person reported on January 19, 2022. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 150% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 150% based on actual achievement of the goal.

SEC source: 0000874015-23-000063 · edgardoc.xml · nonDerivative · entry 2

Cadoret-Manier Onaiza · CIK 0001799355 · EVP, Chf GL Pdt Str & Oper Ofc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,538

F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.25 to $39.70 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

SEC source: 0000874015-23-000063 · edgardoc.xml · derivative · entry 3

Cadoret-Manier Onaiza · CIK 0001799355 · EVP, Chf GL Pdt Str & Oper Ofc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,326

Underlying: Common Stock · 10,197 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-23-000063 · edgardoc.xml · nonDerivative · entry 1

Cadoret-Manier Onaiza · CIK 0001799355 · EVP, Chf GL Pdt Str & Oper Ofc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,286

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

SEC source: 0000874015-23-000043 · edgardoc.xml · derivative · entry 2

Cadoret-Manier Onaiza · CIK 0001799355 · EVP, Chf GL Pdt Str & Oper Ofc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,523

Underlying: Common Stock · 19,460 shares

Expires not disclosed

F3 · security: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-23-000043 · edgardoc.xml · derivative · entry 1

Cadoret-Manier Onaiza · CIK 0001799355 · EVP, Chf GL Pdt Str & Oper Ofc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,635

Underlying: Common Stock · 16,216 shares

Expires not disclosed

F1 · security: Grant to reporting person of Performance Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F2 · derivative.exercise_date: Represents an award of performance based restricted stock units ("PRSUs"). The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.

F2 · derivative.expiration_date: Represents an award of performance based restricted stock units ("PRSUs"). The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.

SEC source: 0001209191-23-003178 · doc4.xml · derivative · entry 1

Cadoret-Manier Onaiza · CIK 0001799355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,880

Underlying: Common Stock · 12,880 shares

Expires 2033-01-11

F1 · derivative.exercise_date: One-thirty sixth (1/36th) of the Shares subject to the option will be scheduled to vest each month following the grant date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Company's 2021 Equity Incentive Plan) through the applicable vesting date.

SEC source: 0000899243-23-011815 · doc4a.xml · derivative · entry 1

Cadoret-Manier Onaiza · CIK 0001799355 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,427

Underlying: Common Stock · 20,427 shares

Expires 2033-01-11

F1 · shares: The Form 4 filed on January 12, 2023, erroneously reported that reporting person received an option award for 12,880 shares on January 11, 2023. The correct option award amount is for 20,427 shares.

F2 · derivative.exercise_date: One-thirty sixth (1/36th) of the Shares subject to the option will be scheduled to vest each month following the grant date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Company's 2021 Equity Incentive Plan) through the applicable vesting date.

F1 · derivative.underlying_shares: The Form 4 filed on January 12, 2023, erroneously reported that reporting person received an option award for 12,880 shares on January 11, 2023. The correct option award amount is for 20,427 shares.

F1 · balance_after: The Form 4 filed on January 12, 2023, erroneously reported that reporting person received an option award for 12,880 shares on January 11, 2023. The correct option award amount is for 20,427 shares.

SEC source: 0000874015-23-000012 · edgardoc.xml · derivative · entry 1

Cadoret-Manier Onaiza · CIK 0001799355 · EVP, Chf GL Pdt Str & Oper Ofc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,946

Underlying: Common Stock · 25,946 shares

Expires 2033-01-02

F1 · derivative.exercise_date: Grant on 01/03/2023 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/03/2023. 25% of the shares subject to the option will vest and become exercisable on 01/03/2024. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0001567619-22-013085 · doc1.xml · derivative · entry 2

Cadoret-Manier Onaiza · CIK 0001799355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2032-06-15

F2 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program.

F3 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date.

SEC source: 0001567619-22-013085 · doc1.xml · nonDerivative · entry 1

Cadoret-Manier Onaiza · CIK 0001799355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,395

F1 · shares: The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program.

SEC source: 0000874015-22-000099 · edgardoc.xml · derivative · entry 3

Cadoret-Manier Onaiza · CIK 0001799355 · EVP, Chf Pdt Str & Oper Ofc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,063

Underlying: Common Stock · 5,667 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F4 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

F4 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

SEC source: 0000874015-22-000099 · edgardoc.xml · nonDerivative · entry 2

Cadoret-Manier Onaiza · CIK 0001799355 · EVP, Chf Pdt Str & Oper Ofc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,089

F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

SEC source: 0000874015-22-000099 · edgardoc.xml · nonDerivative · entry 1

Cadoret-Manier Onaiza · CIK 0001799355 · EVP, Chf Pdt Str & Oper Ofc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,049

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

SEC source: 0000874015-22-000057 · edgardoc.xml · derivative · entry 3

Cadoret-Manier Onaiza · CIK 0001799355 · EVP, Chf Corp Dev and Cml Offc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,730

Underlying: Common Stock · 6,057 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F4 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

F4 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

SEC source: 0000874015-22-000057 · edgardoc.xml · nonDerivative · entry 2

Cadoret-Manier Onaiza · CIK 0001799355 · EVP, Chf Corp Dev and Cml Offc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,382

F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

SEC source: 0000874015-22-000057 · edgardoc.xml · nonDerivative · entry 1

Cadoret-Manier Onaiza · CIK 0001799355 · EVP, Chf Corp Dev and Cml Offc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,687

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

SEC source: 0000874015-22-000034 · edgardoc.xml · derivative · entry 2

Cadoret-Manier Onaiza · CIK 0001799355 · EVP, Chf Corp Dev and Cml Offc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,787

Underlying: Common Stock · 16,559 shares

Expires not disclosed

F3 · security: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

SEC source: 0000874015-22-000034 · edgardoc.xml · derivative · entry 1

Cadoret-Manier Onaiza · CIK 0001799355 · EVP, Chf Corp Dev and Cml Offc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,419

Underlying: Common Stock · 12,419 shares

Expires not disclosed

F1 · security: Grant to reporting person of Performance Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F2 · shares: Represents an award of performance based restricted stock units ("PRSUs"). One-third of the PRSUs may vest at the end of three separate performance periods spread over the three years following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 150% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of each performance period may be anywhere from zero to the amount stated.

F2 · derivative.exercise_date: Represents an award of performance based restricted stock units ("PRSUs"). One-third of the PRSUs may vest at the end of three separate performance periods spread over the three years following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 150% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of each performance period may be anywhere from zero to the amount stated.

F2 · derivative.expiration_date: Represents an award of performance based restricted stock units ("PRSUs"). One-third of the PRSUs may vest at the end of three separate performance periods spread over the three years following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 150% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of each performance period may be anywhere from zero to the amount stated.

SEC source: 0000874015-22-000010 · edgardoc.xml · derivative · entry 1

Cadoret-Manier Onaiza · CIK 0001799355 · EVP, Chf Corp Dev and Cml Offc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,118

Underlying: Common Stock · 33,118 shares

Expires 2032-01-02

F1 · derivative.exercise_date: Grant on 01/03/2022 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/03/2022. 25% of the shares subject to the option will vest and become exercisable on 01/03/2023. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-21-000152 · edgardoc.xml · nonDerivative · entry 1

Cadoret-Manier Onaiza · CIK 0001799355 · Chief Corp Dev and Cml Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,630

F1 · kind: Reporting shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 31, 2021. These shares may not be sold until February 28, 2022.